The effect of penetration enhancers on permeation kinetics of nitrendipine in two different skin models

Biological and Pharmaceutical Bulletin

Volumn 31, Issue 9, 2008, Pages 1766-1772

  Mittal, Ashu ^a   Sara, Udai Vir Singh ^b   Ali, Asgar ^c   Aqil, Mohammed ^c  

^a ITS Paramedical College (Pharmacy)   (India)

^b DJ College of Dental Sciences and Research   (India)

^c HAMDARD UNIVERSITY   (India)

Author keywords

Heat separated skin; Nitrendipine; Oleic acid; Permeation; Rat abdominal skin

Indexed keywords

BASIL OIL; DECANOIC ACID; DIMETHYL SULFOXIDE; DODECYL SULFATE SODIUM; ESSENTIAL OIL; LAURIC ACID; MYRISTIC ACID; MYRISTIC ACID ISOPROPYL ESTER; NITRENDIPINE; OLEIC ACID; PALMAROSA OIL; PENETRATION ENHANCING AGENT; PETIT GRAIN OIL; POLYSORBATE 20; POLYSORBATE 80; SORBITAN OLEATE; SURFACTANT; THYME OIL; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG SCREENING; DRUG SOLUBILITY; EXPERIMENTAL MODEL; HUMAN; HUMAN TISSUE; NONHUMAN; PARAMETER; RAT; SKIN PENETRATION; SKIN PERMEABILITY; TRANSPORT KINETICS;

ADMINISTRATION, CUTANEOUS; ANIMALS; CALCIUM CHANNEL BLOCKERS; DATA INTERPRETATION, STATISTICAL; DIMETHYL SULFOXIDE; EXCIPIENTS; FATTY ACIDS, NONESTERIFIED; HUMANS; MYRISTATES; NITRENDIPINE; OLEIC ACID; PLANT OILS; RATS; SKIN ABSORPTION; SOLUBILITY; STIMULATION, CHEMICAL;

EID: 51549084022     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.31.1766     Document Type: Article

References (46)

1. Chien Y. W., "Controlled Drug Delivery Fundamentals and Application," 2nd ed., Marcel Dekker, New York, 1987.
2. Aronoff G. R., Sloan R. S., Clin. Pharmacol. Ther., 38, 212-218 (1985).
3. Kann J., Krol G. J., Raemsch K. D., Burkholder D. E., Levitt M. J., J. Cardiovasc. Pharmacol., 6(Suppl. 7), S969-S997 (1984).
4. Goa L. K., Sorkin E. M., Drugs, 33, 123-155 (1987).
5. Diez I., Colom H., Moreno J., Obach R., Peraire C., Domenech J. A., J. Pharm. Sci., 80, 931-934 (1991).
6. Reichling J., Landvatter U., Wagner H., Kostka K. H., Schaefer U. F., Eur. J. Pharm. Biopharm., 64, 222-228 (2006).
7. Godwin D. A., Michniak B. B., Drug Dev. Ind. Pharm., 25, 905-917 (1999).
8. Philip G. C., Richard H. G., Hadgraft J., Int. J. Pharm., 48, 103-111 (1988).
9. Cooper E., Merritt E., Smith R., J. Pharm. Sci., 74, 688-689 (1985).
10. Ronald C. W., Patrick K. N., J. Pharm., 7, 99-110 (1980).
11. Schaefer U., Loth H., Pharm. Res., 13(Suppl.), 366 (996).
12. Kligman A. M., Christopers E., Arch. Dermatol., 88, 702-705 (1963).
13. Tipre D. N., Vavia P. R., J. Pharm. Biomed. Anal., 24, 705-714 (2001).
14. Williams A. C., Barry B. W., Pharm. Res., 8, 17-24 (1991).
15. Okamato H., Komatsu H., Hashida M., Sezaki H., Int. J. Pharm., 30, 35-45 (1989).
16. Akhter S. A., Barry B. W., J. Pharm. Pharmacol., 36(Suppl.), 7 (1984).
17. Cooper E. R., J. Pharm. Sci., 73, 1153-1156 (1984).
18. Almirall M., Montana J., Escribano E., Obach R., Berrozpe J. D., Drug Res., 46, 676-680 (1996).
19. Goodman M., Barry B. W., Int. J. Pharm., 57, 29-40 (1989).
20. Funke A. P., Schiller R., Motzkus H. W., Gunther C., Muller R. H., Pharm. Res., 19, 661-668 (2002).
21. Santoyo S., Arellano A., Ygartuna P., Martin C., Int. J. Pharm., 117, 219-224 (1995).
22. Kim C. K., Kim J. J., Chi S. C., Shim C. K., Int. J. Pharm., 43, 31-40 (1993).
23. Park E. S., Kim H., Int. J. Pharm., 126, 267-274 (1995).
24. Takahashi K., Rytting J. H., J. Pharm. Pharmacol., 53, 789-794 (2001).
25. Touitou E., Godin B., Karl Y., Buianover S., Becker Y., J. Controlled Release, 80, 1-7 (2002).
26. Barry B., J. Controlled Release, 6, 85-97 (1987).
27. Walker R. B., Eric W., Smith E. W., Adv. Drug Deliv. Rev., 18, 295-301 (1996).
28. Ongipipattanakul B., Burnette R. R., Potts R. O., Francorur M. L., Pharm. Res., 8, 350-354 (1991).
29. Bond J., Barry B. W., J. Invest. Dermatol., 6, 810-813 (1988).
30. Godwin D. A., Michniak B. B., Drug Dev. Ind. Pharm., 25, 905-911 (1999).
31. Williams A. C., Barry B. W., Pharm. Res., 8, 17-24 (1991).
32. Goa S., Singh J., J. Controlled Release, 51, 193-199 (1998).
33. Vaddi H. K., Ho P. C., Chan S. Y., J. Pharm. Sci., 91, 1639-1651 (2002).
34. Hadgraft J., Eur. J. Pharm. Sci., 4(Suppl.), S38 (1996).
35. Chowan Z. Y., Pritchard R., J. Pharm. Sci., 67, 1272-1274 (1978).
36. Lopez A., Llinares F., Cortell C., Herraez M., Int. J. Pharm., 202, 133-140 (2000).
37. Aunngst B. T., Rogers N. J., Shefter E., Int. J. Pharm., 333, 225-234 (1986).
38. Walters K. A., "Transdermal Drug Delivery Development Issues and Research," Dekker, New York, 1989.
39. Angbogu A. N. C., Andrian C., Williams A. C., Barry B. W., Edwards G. M., Int. J. Pharm., 125, 265-282 (1995).
40. Babar A., Solanki U. D., Cotie A. J., Plakogiannis F., Drug Dev. Ind. Pharm., 16, 523-540 (1990).
41. Reddy L. H., Ghosh B., Indian J. Exp. Biol., 39, 47-51 (2001).
42. Remane Y., Leopold C., Maibach H. I., J. Pharmacokinet. Pharmacodyn., 33, 719-735 (2006).
43. Barrier C. F., Timothy M. M., J. Pharm. Sci., 88, 985-958 (1999).
44. Barry B. W., J. Controlled Release, 5, 43-51 (1987).
45. Ruland A., Kreuter J., Int. J. Pharm., 85, 7-17 (1992).
46. Sato K., Sugibayashi K., Morimoto Y., Int. J. Pharm., 43, 31-40 (1983).